Updated:
BrainCool AB
BrainCool AB is a Swedish medtech company developing portable cooling systems for neurological and dermatological conditions, listed on Nasdaq First North.
BrainCool AB
BrainCool AB was founded in 2008 and is headquartered in Lund, Sweden. The company emerged from research at Lund University on therapeutic hypothermia and has since developed a portfolio of cooling platforms for acute medical applications. The company operates primarily through two platforms: RhinoChill, a noninvasive nasal cooling device for neuroprotection, and PolarCool, a portable cooling system for management of sports-related concussions and for dermatology applications. BrainCool listed on the Nasdaq First North Growth Market in 2015 to fund clinical trials and commercialization. Products target hospital emergency departments, intensive care units, and sports medicine clinics. Geographic focus includes Europe and the United States, with regulatory clearance from the FDA for the RhinoChill system. As of 2025, BrainCool had fewer than 50 employees and relied on grant funding from the European Union's Horizon 2020 program. The company has not disclosed total capital raised or revenue. In August 2022, BrainCool announced a partnership with the NFL to study the PolarCool system for concussion management (per the firm, August 2022). No charitable or family-office entities are associated with the company. BrainCool is a publicly traded entity, not a family office. Its board of directors includes representatives from academia and the medical device industry. The company distinguishes itself through a focus on noninvasive, portable cooling technology for indications where hypothermia has shown therapeutic benefit but existing devices are invasive or bulky.
General information
Firm type
Public MedTech Company
Year founded
2008
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Lund
Corporate office
Lund, Sweden
Sector focus
Frequently asked questions
Who manages investment decisions at BrainCool AB?
BrainCool AB is a publicly traded company managed by a board of directors and executive team. The CEO as of 2025 is Martin Weörell, per public record. Decisions are made by the board, not by any single family or investment principal.
How does BrainCool AB generate revenue?
BrainCool sells its cooling systems—primarily RhinoChill and PolarCool—to hospitals, clinics, and sports organizations. Revenue comes from device sales and consumables. The company has not publicly disclosed revenue figures.
Is BrainCool AB a family office or investment vehicle?
No. BrainCool AB is a publicly listed medical device company on the Nasdaq First North Growth Market. It does not manage capital for any family or outside investors—it is an operating company.
What does BrainCool AB's product pipeline consist of?
The RhinoChill device is used for neuroprotection in stroke and cardiac arrest. The PolarCool system targets concussion management in sports. The company is also exploring dermatology applications for the PolarCool platform (per the firm's website).
What geographic markets does BrainCool AB operate in?
BrainCool's primary markets are Europe and the United States. The RhinoChill system has FDA clearance for noninvasive nasal cooling. The company has distribution partnerships in select countries but relies heavily on grant funding for clinical expansion.
What is the ownership structure of BrainCool AB?
BrainCool AB is a public company with shares traded on the Nasdaq First North Growth Market. Major shareholders includes investment funds and retail investors—no single family or entity controls a majority stake.
Does BrainCool AB engage in any philanthropic or non-profit activities?
There is no evidence that BrainCool AB operates a philanthropic arm. Its activities are limited to commercial development of medical devices and clinical research partnerships.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: